We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+62.1%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.18B
AUM Growth
+$1.19B
Cap. Flow
+$143M
Cap. Flow %
3.41%
Top 10 Hldgs %
48.69%
Holding
88
New
15
Increased
28
Reduced
14
Closed
24
Avg Time Held
5.1 quarters
Top 10 Avg Time Held
3.8 quarters
Top 20 Avg Time Held
4.1 quarters

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$127M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$72.2M
3
BSX icon
Boston Scientific
BSX
+$68.3M
4
APRE icon
Aprea Therapeutics
APRE
+$62.5M
5
UNH icon
UnitedHealth
UNH
+$52.9M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$155M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$114M
3
BOLD icon
Audentes Therapeutics, Inc
BOLD
+$87.2M
4
CELG
Celgene Corp
CELG
+$55.9M
5
WMGI
Wright Medical Group Inc
WMGI
+$49.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Industrials 0.33%
3 Technology 0%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
DCPH icon
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$293M 7.01%
4,709,498
-71,400
-1% -$3.39M
2017 Q3
9 quarters
ALLK icon
2
DELISTED
Allakos
ALLK
$289M 6.92%
3,033,526
-43,602
-1% -$3.83M
2018 Q3
5 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$246M 5.87%
25,209,964
+2,419,830
+11% +$22.2M
2013 Q2
26 quarters
FATE icon
4
Fate Therapeutics
FATE
$230M
$220M 5.25%
11,216,809
– –
2015 Q2
18 quarters
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$215M 5.15%
8,746,033
+109,100
+1% +$1.62M
2017 Q3
9 quarters
ARGX icon
6
argenx
ARGX
$51.9B
$185M 4.43%
1,153,232
+72,800
+7% +$9.85M
2017 Q4
8 quarters
QURE icon
7
uniQure
QURE
$1.42B
$183M 4.38%
2,553,325
+143,200
+6% +$7.86M
2018 Q2
6 quarters
PRNB
8
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$149M 3.57%
2,722,388
+1,932,382
+245% +$72.2M
2019 Q2
2 quarters
BIIB icon
9
Biogen
BIIB
$34B
$136M 3.25%
+457,500
New +$127M
2019 Q4
0 quarters
IGMS icon
10
DELISTED
IGM Biosciences
IGMS
$120M 2.87%
3,144,000
– –
2019 Q3
1 quarter
BMY icon
11
Bristol-Myers Squibb
BMY
$120B
$116M 2.76%
1,800,800
-451,800
-20% -$25.9M
2018 Q4
4 quarters
NVRO icon
12
DELISTED
NEVRO CORP.
NVRO
$110M 2.64%
939,164
+295,300
+46% +$29.2M
2019 Q1
3 quarters
FTSV
13
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$109M 2.61%
2,770,842
+1,143,344
+70% +$18.4M
2019 Q2
2 quarters
APRE icon
14
Aprea Therapeutics
APRE
$7.5M
$104M 2.49%
+113,436
New +$62.5M
2019 Q4
0 quarters
RGNX icon
15
Regenxbio
RGNX
$457M
$103M 2.46%
2,508,386
+145,900
+6% +$5.76M
2017 Q1
11 quarters
CNC icon
16
Centene
CNC
$34.1B
$97.6M 2.33%
1,552,598
+742,100
+92% +$40.3M
2019 Q2
2 quarters
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
$80.4M 1.92%
2,129,100
+51,400
+2% +$1.92M
2018 Q2
6 quarters
ATRA icon
18
Atara Biotherapeutics
ATRA
$94.5M
$76.6M 1.83%
185,943
+5,154
+3% +$1.78M
2014 Q4
20 quarters
IMGN icon
19
DELISTED
Immunogen Inc
IMGN
$74.7M 1.79%
14,639,960
+23,400
+0.2% +$79.4K
2017 Q1
11 quarters
BSX icon
20
Boston Scientific
BSX
$61.6B
$73.8M 1.76%
+1,631,200
New +$68.3M
2019 Q4
0 quarters
TNDM icon
21
Tandem Diabetes Care
TNDM
$1.13B
$69.9M 1.67%
1,172,232
+11,831
+1% +$730K
2018 Q3
5 quarters
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$63.9M 1.53%
+3,237,700
New +$51.8M
2019 Q4
0 quarters
KRYS icon
23
Krystal Biotech
KRYS
$9.56B
$60.4M 1.44%
1,090,200
+11,900
+1% +$584K
2018 Q4
4 quarters
UNH icon
24
UnitedHealth
UNH
$348B
$59.7M 1.43%
203,100
+202,129
+20,817% +$52.9M
2016 Q3
13 quarters
NVS icon
25
Novartis
NVS
$278B
$54.3M 1.3%
+573,100
New +$51.4M
2019 Q4
0 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2019 Portfolio in Review

As of Q4 2019, Redmile Group held 88 positions worth $4.18B, up 40% from $2.99B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group deployed $143M of net new capital in Q4 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Biogen: 457,500 shares worth $136M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Audentes Therapeutics, Inc, an estimated $87.2M trimmed.

  • Redmile Group's largest Q4 2019 buy was Biogen: 457,500 shares worth $136M.
  • Redmile Group added most to Principia Biopharma Inc. Common Stock in Q4 2019, an estimated $72.2M increase.
  • Redmile Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $87.2M.
  • Redmile Group fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $155M.
  • Redmile Group's ten largest holdings make up 49% of its $4.18B portfolio in Q4 2019.
  • Redmile Group opened 15 new positions and closed 24 in Q4 2019.
  • Redmile Group's portfolio value rose 40% quarter-over-quarter to $4.18B.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.